Symbols / ASRT Stock $23.43 -0.04% Assertio Holdings, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NCM
ASRT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Mark L. Reisenauer
Exch · Country NCM · United States
Market Cap 151.41M
Enterprise Value 120.15M
Income -35.69M
Sales 102.16M
FCF (ttm) 7.75M
Book/sh 11.73
Cash/sh 11.07
Employees 53
Insider 10d —
IPO Dec 03, 1997
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 9.08
PEG 0.89
P/S 1.48
P/B 2.00
P/C —
EV/EBITDA 31.40
EV/Sales 1.18
Quick Ratio 1.45
Current Ratio 1.82
Debt/Eq 53.30
LT Debt/Eq —
EPS (ttm) -5.55
EPS next Y 2.58
EPS Growth —
Revenue Growth -62.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-10
Earnings (prior) 2026-05-08
ROA -5.71%
ROE -38.76%
ROIC —
Gross Margin 70.33%
Oper. Margin -185.95%
Profit Margin -34.94%
Shs Outstand 6.46M
Shs Float 5.57M
Insider Own 1.97%
Instit Own 39.94%
Short Float 3.91%
Short Ratio 0.55
Short Interest 249.30K
52W High 23.46
vs 52W High -0.13%
52W Low 8.61
vs 52W Low 172.13%
Beta 0.45
Impl. Vol. 1.81%
Rel Volume 0.63
Avg Volume 291.53K
Volume 184.79K
Target (mean) $24.43
Tgt Median $23.50
Tgt Low $21.80
Tgt High $28.00
# Analysts 3
Recom None
Prev Close $23.44
Price $23.43
Change -0.04%
About

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$24.43
Mean price target
2. Current target
$23.43
Latest analyst target
3. DCF / Fair value
$21.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$23.43
Low
$21.80
High
$28.00
Mean
$24.43

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-13 main Lake Street Hold → Hold $24
2026-05-05 main HC Wainwright & Co. Neutral → Neutral $22
2026-04-09 down Lake Street Buy → Hold $18
2026-04-09 down HC Wainwright & Co. Buy → Neutral $18
2026-01-05 main HC Wainwright & Co. Buy → Buy $35
2025-08-12 main HC Wainwright & Co. Buy → Buy $3
2025-05-19 reit HC Wainwright & Co. Buy → Buy $4
2025-03-19 main HC Wainwright & Co. Buy → Buy $4
2024-12-16 reit HC Wainwright & Co. Buy → Buy $4
2024-11-25 reit HC Wainwright & Co. Buy → Buy $4
2024-07-26 init Maxim Group — → Buy $3
2024-07-03 init HC Wainwright & Co. — → Buy $4
2024-05-28 init Alliance Global Partners — → Buy $3
2024-03-12 main Lake Street Buy → Buy $3
2023-11-03 main BWS Financial Buy → Buy $4
2023-08-04 reit BWS Financial Buy → Buy $6
2023-05-10 main Lake Street Buy → Buy $9
2023-05-10 main BWS Financial Buy → Buy $10
2023-03-03 main BWS Financial — → Buy $8
2022-11-07 init Lake Street — → Buy $7
News
RSS: Latest ASRT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-10 STARK DAVID MATTHEW Director — 8,959 $0.76 $6,806
2025-05-30 O'GRADY BRENDAN P Chief Executive Officer — 166,665 — —
2025-05-12 PATEL AJAY Chief Financial Officer — 38,017 — —
2025-05-12 SCHWICHTENBERG PAUL Officer — 38,017 — —
2025-05-12 SCHLESSINGER SAM General Counsel — 38,017 — —
2025-05-07 EMANY SRAVAN KUMAR Director — 53,750 — —
2025-05-07 KIRK SIGURD C Director — 53,750 — —
2025-05-07 MCKEE WILLIAM T Director — 53,750 — —
2025-05-07 MASON HEATHER L. Director — 53,750 — —
2025-05-07 STARK DAVID MATTHEW Director — 53,750 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
118.71
-5.00%
124.96
-17.83%
152.07
-2.67%
156.23
Operating Revenue
118.71
-3.38%
122.86
-19.11%
151.88
-3.58%
157.52
Cost Of Revenue
35.38
-9.80%
39.23
+45.18%
27.02
+44.12%
18.75
Reconciled Cost Of Revenue
35.24
-9.74%
39.04
+48.35%
26.32
+46.54%
17.96
Gross Profit
83.33
-2.80%
85.73
-31.44%
125.05
-9.05%
137.49
Operating Expense
100.55
-3.79%
104.52
-4.12%
109.01
+37.30%
79.39
Research And Development
1.69
-55.78%
3.82
+34.44%
2.84
0.00
Selling General And Administration
69.00
-8.06%
75.05
-4.56%
78.64
+68.08%
46.79
Total Expenses
135.94
-5.43%
143.74
+5.67%
136.03
+38.60%
98.14
Operating Income
-17.22
+8.31%
-18.78
-217.09%
16.04
-72.39%
58.09
Total Operating Income As Reported
-21.54
+12.01%
-24.48
+89.95%
-243.54
-518.03%
-39.41
EBITDA
2.67
-61.38%
6.90
+103.10%
-222.90
-408.35%
72.29
Normalized EBITDA
15.15
+20.32%
12.59
-65.67%
36.68
-59.68%
90.97
Reconciled Depreciation
30.00
+16.17%
25.83
-8.50%
28.23
-15.47%
33.40
EBIT
-27.34
-44.43%
-18.93
+92.46%
-251.13
-745.73%
38.89
Total Unusual Items
-12.49
-119.34%
-5.69
+97.81%
-259.58
-1289.08%
-18.69
Total Unusual Items Excluding Goodwill
-12.49
-119.34%
-5.69
+97.81%
-259.58
-1289.08%
-18.69
Special Income Charges
-12.49
-119.34%
-5.69
+97.81%
-259.58
-1289.08%
-18.69
Impairment Of Capital Assets
1.70
-67.41%
5.22
-98.13%
279.64
0.00
Restructuring And Mergern Acquisition
2.61
+448.95%
0.48
+102.37%
-20.06
-207.36%
18.69
Net Income
-30.38
-40.75%
-21.58
+93.50%
-331.94
-402.80%
109.62
Pretax Income
-29.94
-39.07%
-21.53
+91.53%
-254.05
-915.16%
31.17
Net Non Operating Interest Income Expense
-0.41
-325.27%
0.18
+101.67%
-10.89
-36.85%
-7.96
Interest Expense Non Operating
2.60
+0.00%
2.60
-11.11%
2.92
-62.14%
7.72
Net Interest Income
-0.41
-325.27%
0.18
+101.67%
-10.89
-36.85%
-7.96
Interest Expense
2.60
+0.00%
2.60
-11.11%
2.92
-62.14%
7.72
Interest Income Non Operating
2.67
-17.26%
3.22
+34.04%
2.40
—
Interest Income
2.67
-17.26%
3.22
+34.04%
2.40
—
Other Income Expense
-12.31
-320.32%
-2.93
+98.87%
-259.20
-1266.73%
-18.96
Other Non Operating Income Expenses
0.18
-93.49%
2.77
+633.42%
0.38
+235.61%
-0.28
Gain On Sale Of Business
-8.17
0.00
—
—
Tax Provision
0.43
+736.54%
0.05
-99.93%
77.89
+199.27%
-78.46
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-2.62
-119.34%
-1.20
+97.81%
-54.51
-1289.08%
-3.92
Net Income Including Noncontrolling Interests
-30.38
-40.75%
-21.58
+93.50%
-331.94
-402.80%
109.62
Net Income From Continuing Operation Net Minority Interest
-30.38
-40.75%
-21.58
+93.50%
-331.94
-402.80%
109.62
Net Income From Continuing And Discontinued Operation
-30.38
-40.75%
-21.58
+93.50%
-331.94
-402.80%
109.62
Net Income Continuous Operations
-30.38
-40.75%
-21.58
+93.50%
-331.94
-402.80%
109.62
Normalized Income
-20.51
-20.06%
-17.08
+86.54%
-126.88
-202.00%
124.39
Net Income Common Stockholders
-30.38
-40.75%
-21.58
+93.50%
-331.94
-402.80%
109.62
Diluted EPS
-4.74
-37.39%
-3.45
+95.07%
-70.05
-330.05%
30.45
Basic EPS
-4.74
-37.39%
-3.45
+95.07%
-70.05
-300.43%
34.95
Basic Average Shares
6.40
+0.81%
6.35
+34.13%
4.74
+51.12%
3.13
Diluted Average Shares
6.40
+0.81%
6.35
+34.13%
4.74
+29.93%
3.64
Diluted NI Availto Com Stockholders
-30.38
-40.75%
-21.58
+93.50%
-331.94
-398.55%
111.19
Average Dilution Earnings
—
—
0.00
-100.00%
1.56
Amortization
29.86
+16.45%
25.64
-6.84%
27.53
-15.58%
32.61
Amortization Of Intangibles Income Statement
29.86
+16.45%
25.64
-6.84%
27.53
-15.58%
32.61
Depreciation Amortization Depletion Income Statement
29.86
+16.45%
25.64
-6.84%
27.53
-15.58%
32.61
Depreciation And Amortization In Income Statement
29.86
+16.45%
25.64
-6.84%
27.53
-15.58%
32.61
Total Other Finance Cost
0.47
+8.20%
0.44
-95.77%
10.37
+4295.34%
0.24
Line Item Trend 2023-12-31
Total Assets
286.42
Current Assets
171.06
Cash Cash Equivalents And Short Term Investments
73.44
Cash And Cash Equivalents
73.44
Other Short Term Investments
0.00
Receivables
47.66
Accounts Receivable
47.66
Gross Accounts Receivable
48.56
Allowance For Doubtful Accounts Receivable
-0.90
Inventory
37.69
Raw Materials
10.54
Work In Process
2.24
Finished Goods
24.91
Prepaid Assets
11.97
Other Current Assets
0.30
Total Non Current Assets
115.36
Net PPE
2.04
Gross PPE
6.67
Accumulated Depreciation
-4.63
Properties
0.00
Machinery Furniture Equipment
1.91
Construction In Progress
0.53
Other Properties
1.29
Leases
2.94
Goodwill And Other Intangible Assets
111.33
Other Intangible Assets
111.33
Investments And Advances
—
Non Current Deferred Assets
0.00
Non Current Deferred Taxes Assets
0.00
Non Current Prepaid Assets
1.29
Other Non Current Assets
0.70
Total Liabilities Net Minority Interest
148.42
Current Liabilities
93.44
Payables And Accrued Expenses
87.35
Payables
13.44
Accounts Payable
13.44
Current Accrued Expenses
73.91
Pensionand Other Post Retirement Benefit Plans Current
2.44
Total Tax Payable
0.00
Current Debt And Capital Lease Obligation
—
Current Debt
—
Other Current Liabilities
3.65
Total Non Current Liabilities Net Minority Interest
54.97
Long Term Debt And Capital Lease Obligation
39.68
Long Term Debt
38.21
Long Term Capital Lease Obligation
1.47
Non Current Deferred Liabilities
5.76
Non Current Deferred Taxes Liabilities
4.55
Other Non Current Liabilities
9.22
Stockholders Equity
138.00
Common Stock Equity
138.00
Capital Stock
0.01
Common Stock
0.01
Share Issued
6.31
Ordinary Shares Number
6.31
Treasury Shares Number
0.00
Additional Paid In Capital
789.54
Retained Earnings
-651.54
Total Equity Gross Minority Interest
138.00
Total Capitalization
176.21
Working Capital
77.62
Invested Capital
176.21
Total Debt
39.68
Net Debt
—
Capital Lease Obligations
1.47
Net Tangible Assets
26.67
Tangible Book Value
26.67
Derivative Product Liabilities
0.31
Interest Payable
0.87
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-28.18
-206.72%
26.41
-46.76%
49.60
-36.89%
78.60
Cash Flow From Continuing Operating Activities
-28.18
-206.72%
26.41
-46.76%
49.60
-36.89%
78.60
Net Income From Continuing Operations
-30.38
-40.75%
-21.58
+93.50%
-331.94
-402.80%
109.62
Depreciation Amortization Depletion
30.00
+16.17%
25.83
-8.50%
28.23
-15.47%
33.40
Depreciation
30.00
+16.17%
25.83
-8.50%
28.23
-15.47%
33.40
Depreciation And Amortization
30.00
+16.17%
25.83
-8.50%
28.23
-15.47%
33.40
Other Non Cash Items
-0.32
+85.78%
-2.23
+85.24%
-15.11
-178.52%
19.24
Stock Based Compensation
3.45
-31.04%
5.01
-45.30%
9.16
+22.04%
7.50
Provisionand Write Offof Assets
4.51
-49.67%
8.96
+172.51%
3.29
+0.70%
3.27
Asset Impairment Charge
1.70
-67.41%
5.22
-98.13%
279.64
0.00
Deferred Tax
—
0.00
-100.00%
76.20
+194.81%
-80.38
Deferred Income Tax
—
0.00
-100.00%
76.20
+194.81%
-80.38
Operating Gains Losses
8.17
—
—
-1.05
Gain Loss On Investment Securities
8.17
—
—
—
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-45.33
-971.12%
5.20
+3617.14%
0.14
+101.08%
-13.01
Change In Receivables
-65.99
-921.99%
-6.46
-113.27%
48.67
+4986.45%
-1.00
Changes In Account Receivables
-65.99
-921.99%
-6.46
-113.27%
48.67
+4986.45%
-1.00
Change In Inventory
9.68
+200.99%
-9.58
-92.70%
-4.97
+24.57%
-6.59
Change In Prepaid Assets
1.21
-72.10%
4.33
+470.74%
-1.17
-114.58%
8.02
Change In Payables And Accrued Expense
9.77
-42.22%
16.91
+139.89%
-42.39
-215.29%
-13.44
Change In Accrued Expense
23.06
+26.95%
18.17
+239.32%
-13.04
-291.44%
-3.33
Change In Payable
-13.29
-958.28%
-1.26
+95.72%
-29.35
-190.20%
-10.11
Change In Account Payable
-13.29
-958.28%
-1.26
+95.72%
-29.35
-190.20%
-10.11
Change In Other Working Capital
—
—
—
—
Investing Cash Flow
-11.99
+75.49%
-48.91
-1679.30%
3.10
+107.26%
-42.67
Cash Flow From Continuing Investing Activities
-11.99
+75.49%
-48.91
-1679.30%
3.10
+107.26%
-42.67
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.63
-129.20%
-0.27
Purchase Of PPE
—
0.00
+100.00%
-0.63
-129.20%
-0.27
Capital Expenditure
—
—
-0.63
-129.20%
-0.27
Net Investment Purchase And Sale
-3.81
+92.20%
-48.91
-2329.31%
2.19
0.00
Purchase Of Investment
-119.20
-20.88%
-98.61
0.00
—
Sale Of Investment
115.38
+132.19%
49.69
+2165.00%
2.19
0.00
Net Business Purchase And Sale
-8.17
0.00
-100.00%
1.53
+103.61%
-42.40
Purchase Of Business
-8.17
0.00
+100.00%
-0.42
+99.01%
-42.40
Gain Loss On Sale Of Business
—
—
—
—
Financing Cash Flow
-0.19
+46.00%
-0.35
+99.21%
-44.20
-467.12%
-7.79
Cash Flow From Continuing Financing Activities
-0.19
+46.00%
-0.35
+99.21%
-44.20
-467.12%
-7.79
Net Issuance Payments Of Debt
—
0.00
+100.00%
-10.50
-1300.00%
-0.75
Issuance Of Debt
—
—
0.00
-100.00%
70.00
Repayment Of Debt
—
0.00
+100.00%
-10.50
+85.16%
-70.75
Long Term Debt Issuance
—
—
0.00
-100.00%
70.00
Long Term Debt Payments
—
0.00
+100.00%
-10.50
+85.16%
-70.75
Net Long Term Debt Issuance
—
0.00
+100.00%
-10.50
-1300.00%
-0.75
Net Common Stock Issuance
-0.19
+46.00%
-0.35
+95.57%
-7.90
-227.76%
6.18
Common Stock Payments
-0.19
+46.00%
-0.35
+95.57%
-7.90
-842.48%
-0.84
Repurchase Of Capital Stock
-0.19
+46.00%
-0.35
+95.57%
-7.90
-842.48%
-0.84
Proceeds From Stock Option Exercised
—
—
—
0.03
Net Other Financing Charges
—
—
-25.80
-95.09%
-13.23
Changes In Cash
-40.36
-76.60%
-22.85
-368.86%
8.50
-69.78%
28.13
Beginning Cash Position
50.59
-31.12%
73.44
+13.09%
64.94
+76.42%
36.81
End Cash Position
10.23
-79.78%
50.59
-31.12%
73.44
+13.09%
64.94
Free Cash Flow
-28.18
-206.72%
26.41
-46.08%
48.98
-37.47%
78.32
Interest Paid Supplemental Data
2.60
+0.00%
2.60
-28.79%
3.65
-52.90%
7.75
Income Tax Paid Supplemental Data
—
1.59
-60.46%
4.03
—
Change In Interest Payable
—
0.00
+100.00%
-0.73
-664.21%
-0.10
Common Stock Issuance
—
—
0.00
-100.00%
7.02
Issuance Of Capital Stock
—
—
0.00
-100.00%
7.02
Sale Of Business
—
0.00
-100.00%
1.95
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category